Meeting
2020 ASCO Virtual Scientific Program
The utility of blood-based molecular tools-the NETest-to monitor and evaluate the efficacy of PRRT in neuroendocrine tumors.
Authors
Lisa Bodei
Memorial Sloan Kettering Cancer Center, New York, NY
Lisa Bodei , Mark S. Kidd , Aviral Singh , Ignat A. Drozdov , Anna Malczewska , Richard P. Baum , Eric Krenning , Irvin Mark Modlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3568)
DOI
10.1200/JCO.2020.38.15_suppl.3568
Abstract #
3568
Poster Bd #
298
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.
First Author: Lisa Bodei
Poster
2023 ASCO Annual Meeting
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
First Author: Erin Frances Cobain
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Annual Meeting
Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs.
First Author: Simron Singh